Physician profile
David M Amron
NPI 1184733214
$2,247.99
in general payments reported to CMS, 2019-2025
13 companies · $575 in 2025
The $575 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $781 · 2020: $73.42 · 2021: $161 · 2022: $154 · 2023: $141 · 2024: $363 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $731.17 | 2020-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Merz North America, INC. | $406.90 | 2019-2022 | |
| Galderma Laboratories, L.P. | $300.63 | 2019-2025 | Dysport |
| Allergan, INC. | $251.81 | 2019-2022 | |
| Apyx Medical Corporation | $191.47 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $99.51 | 2025 | |
| Sun Pharmaceutical Industries INC. | $86.23 | 2019-2023 | Winlevi |
| Abbvie INC. | $70.83 | 2022-2023 | Botox |
| Koya Medical, INC. | $42.03 | 2025 | Dayspring, Koya Medical |
| Vyne Pharmaceuticals INC. | $19.75 | 2021 | |
| Journey Medical Corporation | $18.95 | 2025 | |
| Genentech USA, INC. | $15.90 | 2024 | Xolair |
| Epi Health, LLC | $12.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Amron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.